Wednesday, October 09, 2019
ProciseDx and Lumiphore announced that they have signed an agreement on incorporation of Lumiphore's new metal luminescent reporter technology in ProciseDx™ point-of-care diagnostic tests.
Under the agreement, ProciseDx has the exclusive worldwide rights to use Lumiphore's new technology in its diagnostic tests. First offerings will be for inflammatory and autoimmune diseases such as celiac and metabolic syndromes.
"Lumiphore can bring the benefits of lanthanide-based homogenous mix-and-read assays, known as time-resolved fluorescence resonance energy transfer (TR-FRET) assays, to the diagnostic markets, from central labs to point-of-care applications. Detection sensitivity and simplicity of use as well as material cost reductions in reagent use, labor, and reader platforms are all benefits of Lumiphore's new reporter technology," said Steve Blose, Lumiphore's Chief Business Officer.
"Using Lumiphore's technology enables ProciseDx to offer rapid, quantitative and easy point-of-care tests. We are excited to bring these tests to market in 2020." said Dr. Larry Mimms, ProciseDx's CEO.